PTC Ready to Take Another Shot at FDA Approval of DMD Drug

PTC Ready to Take Another Shot at FDA Approval of DMD Drug

Source: 
BioSpace
snippet: 

For years, PTC Therapeutics has attempted to win regulatory approval for its Duchenne Muscular Dystrophy drug, Translarna (ataluren), but time and time again, the U.S. Food and Drug Administration has rejected the attempts. Now, the company believes it has data that will support another filing for possible approval.